AstraZeneca's rare disease drug ready to enter multi-billion market
- Rare disease drug eplontersen delivers positive trial results - FDA application expected in 2022- Multi-billion-dollar market potentialPharmaceutical giant AstraZeneca (AZN) said a Phase III study of eplontersen to treat a rare...
21 June 2022